ReviewJournal of global antimicrobial resistance2016
Host response to Clostridium difficile infection: Diagnostics and detection.
Review in Journal of global antimicrobial resistance, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Efficacy of UV-C 254 nm Light and a Sporicidal Surface Disinfectant in Inactivating Spores fromPathogens (Basel, Switzerland) · 2024Article
- Testing and Diagnosis of Clostridioides difficile Infection in Special Scenarios: A Systematic Review.Cureus · 2024Review
- Diagnostic Guidance for C. difficile Infections.Advances in experimental medicine and biology · 2024Article
- Prophage Carriage and Genetic Diversity within Environmental Isolates ofInternational journal of molecular sciences · 2023Article
- Article
- Molecular Epidemiology, Clinical Course, and Implementation of Specific Hygiene Measures in Hospitalised Patients withMicroorganisms · 2022Article
- Loop mediated isothermal amplification of Clostridioides difficile isolates in gastrointestinal patients.AMB Express · 2022Article
- Article
- Probiotics Exhibit Strain-Specific Protective Effects in T84 Cells Challenged WithFrontiers in microbiology · 2021Article
- The largely unnoticed spread ofInfection prevention in practice · 2020Review
- IL-17-producing γδ T cells protect against Clostridium difficile infection.The Journal of clinical investigation · 2020Article
- Cytoskeletal Tropomyosin as a Biomarker inJournal of clinical medicine research · 2019Article
- Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Fecal Host Transcriptomics for Non-Invasive Human Mucosal Immune Profiling: Proof of Concept inPathogens & immunity · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Clostridium difficile infection (CDI) is a significant healthcare concern worldwide, and C. difficile is recognised as the most frequent aetiological agent of infectious healthcare-associated diarrhoea in hospitalised adult patients. The clinical manifestation of CDI varies from self-limited diarrhoea to life-threatening colitis. Such a broad disease spectrum can be explained by the impact of host factors. Currently, a complex CDI aetiology is widely accepted, acknowledging the interaction between bacteria and the host. C. difficile strains producing clostridial toxins A and B are considered toxigenic and can cause disease; those not producing the toxins are non-pathogenic. A person colonised with a toxigenic strain will not necessarily develop CDI. It is imperative to recognise patients with active disease from those only colonised with this pathogen and to implement appropriate treatment. This can be achieved by diagnostics that rely on host factors specific to CDI. This review will focus on major aspects of CDI pathogenesis and molecular mechanisms, describing host factors in disease progression and assessment of the host response in order to facilitate the development of CDI-specific diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.